Six months after receipt of the second Covaxin dose, participants received booster dose of the same. The trial demonstrated long-term safety with no serious events
The R&D centre will endeavour to bring scientifically advanced biological, biotechnology products and novel drug delivery systems
The brand is now available pan-India through their distribution partner
He has over 29 years of experience in the field of manufacturing, R&D, business and customer service management
Covaxin has proven to be safe, well-tolerated, and immunogenic in paediatric subjects in phase II/III study. Neutralizing antibodies in children on an average 1.7 times higher than in adults
It plans to deliver over 300 million doses to the Indian government
Molnupiravir is an orally administered form of a potent ribonucleoside analog that inhibits the replication of SARS-CoV-2
The company will market it under the brand name Molflu
The company has developed the API in house at its R&D center in Hyderabad
Sucharita brings with her a rich and varied experience of two decades in Information Technology and Financial Services
Subscribe To Our Newsletter & Stay Updated
